Mario Balsa/X
Jun 3, 2025, 10:35
Mario Balsa Shares ASCENT-04 Trial Results in First-Line mTNBC at ASCO25
Mario Balsa, Medical Oncology resident at ICO, shared a post on X:
“Breaking from ASCO25 — ASCENT-04 SG + pembro shines in 1L PD-L1+ (CPS ≥10) mTNBC:
Median PFS: 11.2 vs 7.8 mo (HR: 0.65, p<0.001).
Median DOR: 16.5 vs 9.2 mo.
ORR: 60% vs 53%, with more CRs (13% vs 8%) .
A paradigm shift in 1L mTNBC? Sis boom bah!”
Mario Balsa shared key findings from the ASCENT-04 trial at ASCO25, showing that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival, duration of response, and overall response rate in PD-L1+ first-line metastatic triple-negative breast cancer (mTNBC).
More posts featuring Mario Balsa.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 23:14
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33